What is Lu PSMA (Lutetium-Prostate Specific Membrane Antigen) Therapy?

Lu177 PSMA Therapy is a treatment for patients with prostate cancer, especially those who have become refractory to conventional therapy. Lutetium PSMA therapy helps to slow down the growth of the cancer cells, reduce the size of the tumours and most importantly improve the quality of life of the patients by reducing the pain caused by the cancer.

Many prostate cancers, in particular those that have spread or become resistant to hormonal therapies, express a unique receptor on their cell surface called Prostate Specific Membrane Antigen (PSMA). When Prostate Cancer metastasizes i.e. spreads to other parts of the body, the PSMA receptor is expressed over the sites of metastases as well.

How does Lu PSMA Therapy Work?

Lutetium-177 is a radioactive substance that emits beta radiation, a destructive kind of radiation. Lutetium-177 is bound to a small peptide which attaches to the PSMA receptor expressed on the cancer cell surface. The Lutetium 177 – PSMA complex, thus attached to the prostate cancer cell, then emits killing radiation causing cell death of the cancer cell. Since the penetration of the emitted beta particle is very small, the surrounding normal cells are spared.

How is the Therapy Done?

Lu177 PSMA is administered intravenously. The patient is admitted to the hospital for 24 hours. A kidney function scan called a MAG3/EC scan is done prior to the administration of the Lu177 PSMA.

What are the Side Effects of Lu PSMA Therapy?

Lu177 PSMA is well tolerated. The most common side effects are a slightly dry mouth, fatigue and nausea. There may also be a slight fall in the white blood cells and platelets about 2 – 3 weeks after the Lu177 PSMA administration.

What is the Response Rate With Lu PSMA Therapy?

The response rates of Lu177 PSMA depend on the tumour biology of prostate cancer, the initial Gleason Score, the extent of disease and the responses to prior therapies. Typically, more than 70% of patients demonstrate a reduction in S. PSA and a shrinkage of tumours following Lu177 PSMA therapy.

When would the doctor consider using this Therapy?

Lu PSMA Therapy is a very specific therapy and is used for managing metastatic Prostate Cancer or when Prostate Cancer is no longer responsive to other types of treatment.

What are the Treatment Schedules with Lu PSMA Therapy?

Most patients undergo three-four treatment cycles at intervals of 8-12 weeks. The number of cycles and the interim duration may vary between individuals depending on the response and interim assessments.

Why should I choose the nuclear medicine therapy center at Fortis Memorial & Research Institute (FMRI), Gurugram (Haryana, India)?

The Nuclear Medicine Therapy Centre at FMRI was one of the first institutes to offer Radio-ligand Therapy with Lu PSMA, and today, the center receives patients from the country and from across the world.

Metastasis cancer (prostate & neuroendocrine tumor) treatment blogs

Blog

Blogs

Use of Yttrium 90 (Y-90) and its effects

TARE vs TACE for Hepatocellular Carcinoma and NET patients

My Experience Getting Lu177 PSMA Therapy In India at Fortis Memorial Research Institute (FMRI)

Castration Resistant Prostate Cancer Treatment – Ac225 PSMA Therapy (Targeted Alpha Therapy)

An In-Depth look at Prostate Cancer

Medical Travel to India’s Fortis Memorial Research Institute, India – My Experience

Is PRRT Right for You?

Radio-theranostics: How Tiny Radioactive Molecules are Personalising Cancer Care

131 Iodine MIBG Therapy For Pediatric Neuroblastoma

Everything you need to know about Alpha PSMA Therapy

Lowest Cost of Lu177 PSMA Therapy

What is Transarterial Radioembolization (TARE)

225Ac-PSMA-617 – A New Beginning in the Treatment of Chemotherapy-Naive Prostate Cancer Patients

Which Patients can benefit with PRRT?

Is PRRT Safe for you?

PRRT Treatment Day Overview

Advancements in PRRT for treating Neuroendocrine tumours and other cancers.
A look at Targeted Alpha Therapy

Metastasis directed Lu-177 PSMA Therapy in Prostate Cancer Patients with Oligometastatic Disease

Lu177 PRRT For Neuroendocrine Tumors (Nets)